Results 31 to 40 of about 4,521,628 (366)

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis

JAMA Oncology, 2019
Importance Recently, new drugs have been approved for the first-line treatment of metastatic renal cell carcinoma (mRCC). Nivolumab plus ipilimumab significantly increases overall survival for intermediate- and poor-risk patients with mRCC.
X. Wan, Yucong Zhang, Chongqing Tan, Xiaohui Zeng, L. Peng   +4 more
semanticscholar   +1 more source

Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. [PDF]

, 2008
OBJECTIVE: To compare the cost-effectiveness of eflornithine and melarsoprol in the treatment of human African trypanosomiasis. METHOD: We used data from a Médecins Sans Frontières treatment project in Caxito, Angola to do a formal cost-effectiveness ...
Adam, Blum, Burri, Burri, Chappuis, Commission for Macroeconomics and Health, Edejer, Evans, Goldie, Legros, Louis, Lutumba, Matovu, Murray, Murray, Pepin, Pepin, Pepin, Politi, Priotto, Robays, Schmid, Schmid, Stanghellini   +23 more
core   +2 more sources

A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

JAMA Oncology, 2019
Key Points Question Is unselected genetic testing of all women with breast cancer cost-effective compared with testing based on clinical criteria or family history?
Li Sun, Li Sun, A. Brentnall, Shreeya Patel, Shreeya Patel, D. Buist, E. Bowles, D. Evans, D. Eccles, J. Hopper, Shuai Li, M. Southey, M. Southey, M. Southey, S. Duffy, J. Cuzick, I. D. S. Silva, A. Miners, Z. Sadique, Li Yang, R. Legood, R. Manchanda   +21 more
semanticscholar   +1 more source

Should Research Ethics Encourage the Production of Cost-Effective Interventions? [PDF]

, 2016
This project considers whether and how research ethics can contribute to the provision of cost-effective medical interventions. Clinical research ethics represents an underexplored context for the promotion of cost-effectiveness.
A Briggs, A Fleischman, A Rid, AD Paltiel, AJ London, AJ London, AM Garber, AS Kesselheim, C Grady, CC Denny, D Barnbaum, D Mortimer, D Wendler, DA Hyman, DB Resnik, DJ Torgerson, DM Dimichele, DR Buchanan, E Frank, ED Prentice, EE Roughead, EJ Emanuel, EJ Emanuel, EJ Emanuel, EJ Emanuel, EJ Emanuel, F Baylis, FA Lederle, G Yamey, GA Cohen, GR Wilensky, H Grabowski, HF Lynch, HG Frankfurt, HJ Curzer, I Rudan, J Cohen, J Dowie, J Harris, J McMahan, JA Tobert, JC Lindsey, JW Berg, L Bojke, LP Garrison Jr, M Angell, M Limb, MF Drummond, MJ Mehlman, MS Mano, N Daniels, NMP King, NMP King, PA Ubel, PJ Neumann, PJ Neumann, PR Orszag, PR Orszag, PT Menzel, PT Menzel, PT Menzel, R Dresser, RA Epstein, RA Rettig, RA Spinello, RK Lie, RL Fleurence, S Batt, S Joffe, S Palmer, S Thomson, S Woods, SE Weinberger, SK Shah, T Fojo, T Hurka, T Schrecker, TJ Zywicki, U Schüklenk, WC Black, Z Kmietowicz   +80 more
core   +1 more source

A systematic review and cost effectiveness analysis of reusable vs. single‐use flexible bronchoscopes

Anaesthesia, 2019
The cost effectiveness of reusable vs. single‐use flexible bronchoscopy in the peri‐operative setting has yet to be determined. We therefore aimed to determine this and hypothesised that single‐use flexible bronchoscopes are cost effective compared with ...
J. M. Mouritsen, L. Ehlers, J. Kovaleva, I. Ahmad, I. Ahmad, K. El-Boghdadly, K. El-Boghdadly   +6 more
semanticscholar   +1 more source

Cost-effectiveness analysis. [PDF]

BMJ, 1993
When different health care interventions are not expected to produce the same outcomes both the costs and the consequences of the options need to be assessed. This can be done by cost-effectiveness analysis, whereby the costs are compared with outcomes measured in natural units--for example, per life saved, per life year gained, and per pain or symptom
openaire   +2 more sources

Diagnostic assessment reviews : is cost-effectiveness analysis helpful or necessary? [PDF]

, 2018
Objective Diagnostic Assessment Reviews are part of the work programme of the National Institute of Health and Care Excellence (NICE) in England to evaluate emergent medical technologies and so ensure timely and consistent adoption within the National
Mason, James, Mistry, Hema
core   +1 more source

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial. [PDF]

, 2019
BackgroundEconomic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated.MethodsTo illustrate ...
Chen, Bingshu E, Dewa, Carolyn S, Hay, Annette, Hoch, Jeffrey S, Isaranuwatchai, Wanrudee, Jonker, Derek, Leighl, Natasha B, Mittmann, Nicole, O'Callaghan, Chris, Pater, Joseph, Thavorn, Kednapa, Trenaman, Logan, Tu, Dongsheng   +12 more
core   +1 more source

Economic evaluation: a reader’s guide to studies of cost-effectiveness

Archives of Physiotherapy, 2022
Background Understanding what an economic evaluation is, how to interpret it, and what it means for making choices in a health delivery context is necessary to contribute to decisions about healthcare resource allocation.
J. Haxby Abbott, Ross Wilson, Yana Pryymachenko, Saurab Sharma, Anupa Pathak, Jason Y. Y. Chua   +5 more
doaj   +1 more source

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis [PDF]

, 2003
OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom. DESIGN: Modelling cost effectiveness.
Abrams, K., Chilcott, J., Claxton, K., Cooper, N.J., McCabe, C., O'Hagan, A., Tappenden, P.   +6 more
core   +2 more sources